AFL vs MET: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
AFL and MET are similarly sized, but MET trades noticeably cheaper on forward earnings (9.04x vs 16.31x): the market is paying up for AFL's profile and pricing MET more conservatively, or for faster growth. Which you prefer comes down to the drivers you believe, and whether adding either over-concentrates what you already own.
AFL vs MET: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | AFL | MET | What it tells you |
|---|---|---|---|
| Market cap | $62.27B | $64.15B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 16.31 | 9.04 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 13.36 | 19.34 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.55 | 0.77 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 76% of range | 93% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 2.06 | 2.35 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Reading it: MET is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how AFL and MET affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AFL and MET share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AFL and MET exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Aflac (AFL) do?
Aflac Incorporated, headquartered in Columbus, Georgia, is the largest provider of supplemental health insurance sold at the worksite in the United States and the leading writer of cancer and medical insurance in Japan. The products are narrow by design: cash-benefit policies that pay the policyholder directly when a covered event happens (a cancer diagnosis, a hospital stay, an accident), sitting alongside rather than replacing major medical coverage. Aflac Japan, distributed through banks, independent agencies and the Japan Post network, is the larger of the two segments and produced pretax adjusted earnings of ~$759 million in Q1 2026 against ~$363 million for Aflac US. Because premiums are small, recurring and paid by payroll deduction or bank draft, the revenue base is unusually stable compared with property, casualty or annuity writers.
What does MetLife (MET) do?
MetLife, Inc. is one of the world's largest providers of life insurance, employee benefits, annuities, and asset management, serving individuals and institutional clients across the United States, Asia, Latin America, Europe, the Middle East, and Africa. It reports through several segments, including Group Benefits (group life, dental, disability, and other workplace coverage), Retirement and Income Solutions (annuities, pension risk transfers, structured settlements, and stable value products), Asia, Latin America, EMEA, and MetLife Holdings, its book of legacy US business. The core model is classic insurance: collect premiums, pay claims and benefits over time, and invest the difference (the float) in a large fixed-income-heavy portfolio, earning a spread. That makes MetLife both an underwriter and a giant investor, so its profitability depends on disciplined pricing, mortality and morbidity trends, and the returns it earns on invested assets.
AFL vs MET: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- AFL drivers: Japan third-sector product refresh; Buyback-driven earnings per share.
- MET drivers: Group Benefits and workplace demand; Retirement and Income Solutions.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The dominant risk is the yen: with the majority of profit earned in Japan, a weaker yen compresses reported dollar earnings and book value even when the underlying business is unchanged, and the enterprise hedging program reduces but does not eliminate the effect. For MET, metLife's biggest risks come from the same levers that drive its profits.
AFL or MET: which should you pick?
AFL vs MET: the full fundamentals
AFL. Aflac's reported revenue and GAAP earnings are noisier than the underlying business because they absorb investment gains and losses and yen translation, which is why the trailing P/E of about 12.8 looks cheaper than the forward multiple of about 15.7 on adjusted estimates. The market has generally valued the stock in the low-to-mid teens on earnings, a discount that reflects the shrinking Japanese premium base and currency exposure, offset by high margins and heavy buybacks. Third-quarter 2026 results are due November 4, 2026, with consensus near $1.80 of adjusted EPS on about $4.21 billion of revenue.
MET. At about $101.80 on October 16, 2026, MetLife trades near 9 times forward adjusted earnings, while the trailing GAAP P/E near 19.5x is inflated by investment and actuarial items that adjusted figures exclude. The 16 analysts tracked by Yahoo Finance hold a mean target near $107, and JPMorgan and Wells Fargo both lifted targets to $110 in mid-October. Insurer results swing with rates, credit markets and assumption updates, so reported and adjusted numbers can differ sharply.
Headline figures (approximate, October 2026): AFL shows revenue (ttm) ~$18.1 billion; Q2 2026 revenue ~$4.22 billion, down ~1% year over year, net earnings (ttm) ~$4.86 billion; Q2 2026 net earnings ~$825 million, adjusted eps Q2 2026 ~$1.75 vs ~$1.76 expected; 2026 consensus ~$7.02, 2027 ~$7.62, market cap ~$60 billion (shares $119.31 on Oct 16, 2026); MET shows revenue (ttm) ~$79.4 billion, up ~10.5% YoY in Q2 2026, net income (ttm) ~$3.4 billion GAAP (~4.6% net margin), adjusted eps Q2 2026 $2.43 vs $2.29 estimate; 2026 consensus ~$10.21, p/e ~19.5x trailing GAAP, ~9x forward adjusted.
The bottom line: AFL vs MET
AFL and MET are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AFL and MET exposure against your real portfolio. It is not an investment adviser.
Wondering how AFL or MET fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Investing in Aflac with AI
Connect the broker you already use and ask Walnut's AI how AFL fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between AFL and MET?
+
Aflac Incorporated, headquartered in Columbus, Georgia, is the largest provider of supplemental health insurance sold at the worksite in the United States and the leading writer of cancer and medical insurance in Japan. MetLife, Inc. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is AFL or MET the better stock?
+
Neither is universally better; they suit different views and risk levels. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, AFL or MET?
+
On forward P/E (as of November 2026), AFL trades at 16.31x and MET at 9.04x, so MET is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both AFL and MET?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of AFL vs MET?
+
AFL: The dominant risk is the yen: with the majority of profit earned in Japan, a weaker yen compresses reported dollar earnings and book value even when the underlying business is unchanged, and the enterprise hedging program reduces but does not eliminate the effect. The second is demographic and structural, because Japan's population is aging and shrinking, the existing cancer and medical block keeps rolling into paid-up status, and net earned premiums there have been declining year over year. A third is that the company faces litigation exposure, including class actions stemming from the June 2025 cyberattack on its network that exposed customer data, plus longstanding disputes with sales associates over classification and sales practices. Interest rate volatility affects both investment income and the valuation of a large fixed-income portfolio, and a sharp move in Japanese government bond yields would hit the Japan investment book directly. Finally, the valuation carries little margin for disappointment: at roughly 13 times trailing GAAP earnings, about 15.7 times forward adjusted estimates and about 2 times book value, with a dividend yield near 2.1% (October 2026), most of the return has to come from execution on Japan sales and the buyback rather than multiple expansion. Analyst sentiment has cooled too: the consensus rating is Hold and the mean target of about $117 sits slightly below the current price. MET: MetLife's biggest risks come from the same levers that drive its profits. As a large investor of policyholder float, it is exposed to interest-rate swings, credit spreads, and equity-market moves: sharp rate changes affect both investment income and the value of long-duration liabilities, and a credit downturn could pressure its bond and commercial-real-estate holdings. Insurance-specific risks include mortality, morbidity, and longevity assumptions proving wrong, plus reserve adequacy on long-tail liabilities like pensions and annuities. Its international earnings add currency and local-regulatory risk. Reported net income can be lumpy because of actuarial assumption updates, derivative marks, and market-related items, which is why the company emphasizes adjusted earnings. Insurance is also heavily regulated and capital-intensive, so statutory capital requirements and rating-agency views constrain how much can be returned to shareholders. After a 27% rise in 2026 the shares sit close to the analyst mean target of about $107 (October 2026), so less of the capital-return story is left unpriced than a year ago.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell AFL or MET; figures are approximate and dated (as of November 2026). Verify current data before investing.